Related Experiment Video
Updated: Feb 24, 2026

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
Published on: May 2, 2025
Checkpoint inhibitors: a cutting edge in oncology
1Clarivate Analytics, London, UK. charlotte.jago@clarivate.com.
Checkpoint inhibitors and immuno-oncology offer significant potential. Future research will focus on optimizing immunotherapy combinations and patient selection for improved outcomes.
Area of Science:
- Immunology
- Oncology
- Pharmacology
Background:
- The field of immuno-oncology, particularly checkpoint inhibitors, is rapidly advancing with substantial clinical and commercial promise.
- Significant challenges remain in determining optimal immunotherapy strategies and identifying suitable patient populations.
Purpose of the Study:
- To highlight the rapid progress and future challenges in the immuno-oncology field.
- To discuss the implications of biomarker-based approvals in cancer treatment.
Main Methods:
- Review of current trends and advancements in immuno-oncology.
- Analysis of key drug approvals and their impact on treatment paradigms.
Main Results:
- Checkpoint inhibitor therapies demonstrate considerable clinical and commercial potential.
- Biomarker-based indications, such as Keytruda's approval, represent a significant step towards personalized cancer treatment.
Conclusions:
- Continued development in immuno-oncology is expected to yield substantial improvements in patient outcomes.
- Personalized approaches, guided by biomarkers, will likely shape the future of cancer immunotherapy.
More Related Videos
06:38An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
Published on: September 12, 2019
10:33Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
Published on: October 26, 2015
Related Concept Videos
Inhibition of Cdk Activity
Targeted Cancer Therapies
There are several types of targeted therapies against...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Tumor Immunotherapy
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...